Vimizim

elosulfase alfa · BioMarin International Limited
AUTHORISED IN THE EU

What Vimizim is used for

Vimizim is indicated for the treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA) in patients of all ages.

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Vimizim
Active substance
elosulfase alfa
Disease area
Mucopolysaccharidosis IV
Medicine group
Other alimentary tract and metabolism products
ATC code
A16AB12
Marketing authorisation holder
BioMarin International Limited
Authorised in the EU since
2014

Official information

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Vimizim used for?

Vimizim is indicated for the treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA) in patients of all ages.

What is the active substance in Vimizim?

Vimizim contains elosulfase alfa.

Who makes Vimizim?

The EU marketing authorisation holder is BioMarin International Limited.

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.